All In Biotech

Drug Trial Radar · NCT00025402

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase

Last checked: Nov 19, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jul 1997

Primary completion

Not stated

Sponsor

Lead sponsor
III. Medizinische Klinik MannheimAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Giving chemotherapy, such as hydroxyurea, cytarabine, idarubicin, and etoposide before a donor bone marrow transplant or stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether chemotherapy is more effective with or without interferon alfa and/or bone marrow or stem cell transplant in treating patients with chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying chemotherapy and biological therapy to see how well it works compared with chemotherapy, biological therapy, and donor bone marrow transplant or autologous stem cell transplant in treating patients with chronic phase chronic myelogenous leukemia.

Conditions

  • Leukemia

Interventions

  • filgrastimBiological

  • recombinant interferon alfaBiological

  • busulfanDrug

  • cyclophosphamideDrug

  • cytarabineDrug

  • etoposideDrug

  • hydroxyureaDrug

  • idarubicinDrug

  • allogeneic bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival
  2. Frequency, time-point, and duration of hematologic and cytogenetic remissions and of Philadelphia chromosome-negative and/or BCL-ABL-positive cells
  3. Correlation of quality of hematological and cytogenetic remission with survival time
  4. Course of the terminal phase
  5. Toxicity
  6. Effect of prognostic criteria and normal or subnormal WBC on chronic phase duration and survival time
  7. Effect of early vs late high-dose therapy and autografting on feasibility, toxicity and survival times

Locations

188 sites in 5 countries. Site status is shown where the registry gives one.

  • Masaryk University Hospital

    Brno, Czechia

  • Haematologisch Onkologische Praxis

    Aachen, Germany

  • Kinderklinik - Universitaetsklinikum Aachen

    Aachen, Germany

  • Urologische Klinik - Universitaetsklinikum Aachen

    Aachen, Germany

  • Kreiskrankenhaus

    Aalen, Germany

  • Klinikum St. Marien

    Amberg, Germany

  • Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

    Ansbach, Germany

  • II. Medizinische Klinik

    Aschaffenburg, Germany

  • Haematologische Praxis

    Augsburg, Germany

  • Klinikum Augsburg

    Augsburg, Germany

  • Kreiskrankenhaus

    Bad Hersfeld, Germany

  • Krankenhaus Hohe Warte Mediziniche Klinik

    Bayreuth, Germany

  • St. Hedwig Kranken Haus

    Berlin, Germany

  • Tumorzentrum Berlin-Moabit

    Berlin, Germany

  • Wenckebach - Krankenhaus

    Berlin, Germany

  • Helios Klinikum Berlin

    Berlin, Germany

  • Haematologisch-Onkologische Schwerpunktpraxis

    Berlin, Germany

  • Charite - Campus Charite Mitte

    Berlin, Germany

  • Onkolog - Haematolog Schwerpunktpraxis

    Berlin, Germany

  • Krankenhaus Neukoelln

    Berlin, Germany

  • Charite - Campus Virchow Klinikum

    Berlin, Germany

  • Kinderklinik der Freier Universitaet Berlin

    Berlin, Germany

  • Onkologische Schwerpunktpraxis Bielefeld

    Bielefeld, Germany

  • Franziskus Hospital

    Bietigheim, Germany

  • Krankenhaus Bietigheim

    Bietigheim, Germany

  • Kreiskrankenhaus Boeblingen

    Böblingen, Germany

  • Europahochhaus

    Bochum, Germany

  • Universitaetsklinikum Bonn

    Bonn, Germany

  • Medizinische Poliklinik

    Bonn, Germany

  • Marienhospital Bottrop gGmbH

    Bottrop, Germany

  • Staedtisches Klinikum Braunschweig

    Braunschweig, Germany

  • Klinikum Bremen-Mitte

    Bremen, Germany

  • St. Joseph Hospital

    Bremerhaven, Germany

  • Zentralkrankenhaus

    Bremerhaven, Germany

  • Medizinische Klinik Am Lukas - Krankenhaus

    Bünde, Germany

  • Klinikum Coburg

    Coburg, Germany

  • Praxis Gemeinschaft

    Cologne, Germany

  • Praxis Fuer Haematologie Internistische Onkologie

    Cologne, Germany

  • Medizinische Universitaetsklinik I at the University of Cologne

    Cologne, Germany

  • Onkologische Schwerpunktpraxis

    Cottbus, Germany

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.